Sofinnova leads investment round


United States

Sofinnova Investments has led a $90 million Series C financing round for Star Therapeutics Inc, the proceeds of which will support one of Star’s portfolio companies called Vega Therapeutics. Based in South San Francisco, US, Star is a biotechnology company consisting of subsidiary enterprises which are each focused on developing products based on specific areas of biology.

In addition to Sofinnova, investors in the oversubscribed round included the Qatar Investment Authority, Catalio Capital Management, Agent Capital, Soleus Capital and NYBC Ventures.